Revolution Medicines (RVMD) Stock Forecast & Price Target $54.10 +4.42 (+8.90%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$54.30 +0.20 (+0.37%) As of 10/17/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Revolution Medicines - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 15 Analyst RatingsSell1Hold0Buy14 Based on 15 Wall Street analysts who have issued ratings for Revolution Medicines in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, 13 have given a buy rating, and 1 has given a strong buy rating for RVMD. Consensus Price Target $76.6741.71% Upside According to the 15 analysts' twelve-month price targets for Revolution Medicines, the average price target is $76.67. The highest price target for RVMD is $99.00, while the lowest price target for RVMD is $66.00. The average price target represents a forecasted upside of 41.71% from the current price of $54.10. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for RVMD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Revolution Medicines and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Analyst Ratings Over TimeTypeCurrent Forecast10/18/24 to 10/18/251 Month Ago9/18/24 to 9/18/253 Months Ago7/20/24 to 7/20/251 Year Ago10/19/23 to 10/18/24Strong Buy1 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)Buy13 Buy rating(s)14 Buy rating(s)11 Buy rating(s)10 Buy rating(s)Hold0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)0 Hold rating(s)Sell1 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$76.67$73.67$68.91$54.00Forecasted Upside41.71% Upside62.91% Upside79.92% Upside7.08% UpsideConsensus RatingModerate BuyBuyBuyBuy RVMD Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History RVMD Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Revolution Medicines Stock vs. The CompetitionTypeRevolution MedicinesMedical CompaniesS&P 500Consensus Rating Score 2.93 2.33 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside41.71% Upside1,357.67% Upside13.61% UpsideNews Sentiment RatingPositive NewsSee Recent RVMD NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/17/2025National Bankshares3 of 5 starsAlex Stranahan Not RatedSet Target$80.00+47.41%10/17/2025Raymond James Financial4 of 5 starsSean McCutcheon Not RatedBoost TargetStrong-Buy$72.00 ➝ $76.00+36.38%10/17/2025Wedbush4 of 5 starsRobert Driscoll Not RatedReiterated RatingOutperform$77.00+54.99%10/15/2025Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLaura PrendergastSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$85.00+71.51%10/8/2025Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingSell (D-)9/12/2025The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrea NewkirkSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$65.00 ➝ $73.00+57.85%9/11/2025Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEva Fortea VerdejoSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$67.00 ➝ $70.00+73.05%9/11/2025Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAmi FadiaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$56.00 ➝ $66.00+63.16%9/5/2025Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAsthika GoonewardeneSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageBuy$99.00+154.17%8/18/2025Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingKelsey GoodwinSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingInitiated CoverageOverweight$75.00+105.76% Get the Latest News and Ratings for RVMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. 8/18/2025Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageOutperform$80.00+120.26%6/25/2025GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMichael SchmidtSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$80.00+104.17%5/14/2025HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingRobert BurnsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingBuy$73.00 ➝ $72.00+79.95%5/8/2025OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJay OlsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$70.00 ➝ $75.00+76.22%1/8/2025UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$65.00 ➝ $71.00+58.09%12/3/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetOverweight$63.00 ➝ $71.00+37.07%9/27/2024BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingP. LawsonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOverweight$54.00 ➝ $60.00+34.80%7/16/2024Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Boost TargetBuy$48.00 ➝ $55.00+19.57%7/8/2024Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageBuy$63.00+67.87%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:56 PM ET. RVMD Forecast - Frequently Asked Questions What is Revolution Medicines' forecast for 2025? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Revolution Medicines is $76.67, with a high forecast of $99.00 and a low forecast of $66.00. Should I buy or sell Revolution Medicines stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There is currently 1 sell rating, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RVMD shares. Does Revolution Medicines's stock price have much upside? According to analysts, Revolution Medicines's stock has a predicted upside of 41.71% based on their 12-month stock forecasts. What analysts cover Revolution Medicines? Revolution Medicines has been rated by research analysts at Lifesci Capital, National Bankshares, Needham & Company LLC, Piper Sandler, Raymond James Financial, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Revolution Medicines more than its competitors? Analysts like Revolution Medicines more than other "medical" companies. The consensus rating for Revolution Medicines is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how RVMD compares to other companies. Stock Forecasts and Research Tools Related Companies ONC Stock Forecast INSM Stock Forecast BNTX Stock Forecast TEVA Stock Forecast GMAB Stock Forecast SMMT Stock Forecast ASND Stock Forecast RDY Stock Forecast VTRS Stock Forecast ROIV Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:RVMD) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
